Due to the exciting developments of molecular biology during the past decade and our increasing understanding of the mechanisms relevant to the genesis of cancer, we are experiencing a transition from disease to target-oriented therapy. This has a strong impact on the development paradigm of cancer therapeutics. Nowhere is this more apparent than in molecular targeted therapy. As with previous meetings, BTOC-11 will focus on the clinical development of a broad spectrum of anti-cancer agents attracting a multi-stakeholder attendance connecting preclinical and clinical scientists, clinicians, healthcare professionals, academia, industry and other stakeholders who are involved in the development of novel anti-cancer agents.